Claudia Pechstein Teil 5 - St. Marien-Krankenhaus Siegen

Minnemann Siehe Morgenthaler
Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R,
Swerdloff RS, Wang C: Long acting testosterone undecanoate
therapy in men with hypogonadism: results of a pharmacokinetic
clinical study. J Urol. 180:2307-2313, 2008
Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I,
Schumann C, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W,
Jockenhövel F: Comparison of a new long-acting testosterone
undecanoate formulation vs testosterone enanthate for intramuscular
androgen therapy in male hypogonadism. Endocrinol Invest. 31:718-
723, 2008.
„Andriol Testcaps“ Alte Männer mit Testosteronmangel erhielten in einer randomisierten
Studie sechs Monate lang zweimal täglich zwei Kapseln Andriol oder
Placebo. Darunter stieg der mittlere Hämoglobinwert von 14.7 auf
15.2 g/dl und der Mittelwert des Hämatokrits von 45 auf 46%.
Publikation frei downloadbar.
Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock
TM, Bosch JL, Grobbee DE, van der Schouw YT: Effect of
testosterone supplementation on functional mobility, cognition, and
other parameters in older men: a randomized controlled trial. JAMA
299: 39-52, 2008
Transsexuelle „Testosterone treatment is essential for the induction and
maintenance of virilization of female-to-male transsexuals. This study
tested the suitability of a novel testosterone preparation for this
purpose. METHODS: Parenteral long-acting testosterone
undecanoate (TU) was administered to 12 female-to-male
transsexuals. Observations were made while subjects received
treatment. MAIN OUTCOME MEASURES: Virilization of female-tomale
transsexuals and side effects of testosterone administration.
RESULTS: The testosterone levels were largely identical to those in
hypogonadal men receiving testosterone treatment with TU. There
were no side effects. There was a small but significant decrease in
plasma cholesterol and low-density lipoprotein, but plasma highdensity
lipoprotein did not change significantly. Both levels of
hemoglobin and hematocrit rose upon administration but remained
within the physiological range. CONCLUSIONS: TU is suited for
induction of virilization in female-to-male transsexuals without
significant side effects.”
Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular
testosterone undecanoate for treatment of female-to-male
transgender individuals. J Sex Med. 4:1479-84. 2007
17